Item 7.01. Regulation FD Disclosure.

As previously announced, PTC Therapeutics, Inc. (the "Company") will host a conference call on September 23, 2021 at 8:00 a.m. eastern time. During this conference call, the Company expects to discuss the results from the PTC518 Phase 1 healthy volunteer study and provide an update on the PTC518 Phase 2 study, to be conducted in Huntington's disease patients. A copy of the slide deck that will be presented during the conference call is attached as Exhibit 99.1.

The information in this Report (including Item 7.01 and Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits


Exhibit No.                                Description
                  Corporate Presentation - PTC518 Huntington's Disease Program
    99.1        Update
                The cover page from this Current Report on Form 8-K, formatted in
    104         Inline XBRL

© Edgar Online, source Glimpses